KRAS and cancer: The reduction of elevated RAS protein levels caused by APC and KRAS mutations might be an ideal therapeutic strategy that can target both CSCs and non-CSC cancer cells that have the potential to dedifferentiate into CSCs, without causing toxicity to healthy stem cells.